Oral Argument in Medtronic Inc. v. Boston Scientific Corp.

by McDonnell Boehnen Hulbert & Berghoff LLP

Supreme Court Courtroom_cOn November 5, 2013, the Supreme Court heard oral arguments in the Medtronic Inc. v. Boston Scientific Corp. case (Supreme Court docket number 12-1128).  The sole issue on appeal was who has the burden of proof on the issue of infringement/non-infringement in a declaratory judgment action brought by a licensee under Medlmmune, the licensee (DJ Plaintiff) or the patent holder/licensor.  The Federal Circuit had decided that, in such cases, it is the licensee that seeks to disturb the status quo ante, and therefore it should bear the burden of proof.  However, if the tenor of the questioning is any indication, it would appear that the Justices did not necessarily agree.

This problem presented by this case is a direct consequence of the Court's MedImmune decision several years ago.  In that case (as well as all similarly situated cases that have followed), the parties had entered into a patent licensing agreement, and while the license was maintained, the licensee was under no risk of facing a patent infringement suit.  However, the licensee wanted relief from royalty payments related to one of the licensed patents, but at the same time did not want to repudiate the entire contract.  Because the patent holder could not bring an infringement suit, there was a question about whether a case or controversy actually existed such that a declaratory judgment action could be brought.  The Supreme Court answered in the affirmative, reasoning that "[t]he rule that a plaintiff must destroy a large building, bet the farm, or (as here) risk treble damages and the loss of 80 percent of its business, before seeking a declaration of its actively contested legal rights finds no support in Article III."  Medlmmune, Inc. v. Genentech, Inc., 549 U.S. 118, 134 (2007).  In other words, the Court created what appeared to be a patent-license exception to the Article III case-or-controversy requirement, because the licensee was not under the threat of an infringement action.  Indeed, without repudiation, the patent holder could not even bring a counterclaim of patent infringement in such a case.  However, the logical underpinning of this apparently "artificial" satisfaction of the case-or-controversy requirement began to come unhinged when you consider the issue of who bears the burden of proof in such a case.  This was all too apparent during the oral argument as the Justices grappled with the issue.

MedtronicInterestingly, the Court had minimal questions for Medtronic (the licensee).  In fact, most of the questioning during this part of the hearing was directed at ensuring the Justices had a correct understanding of the facts and procedural posture underlying this case.  For example, when counsel for Medtronic pointed out that this case was about the ordering of proofs in patent cases, Justice Alito stated that "if that's all that's involved, then the case doesn't seem to amount to quite as much as one might have thought otherwise, does it?"  The counsel representing the Solicitor General's office, which argued in favor of Medtronic, faced even less interrogation from the Court.  In fact, only three questions were asked by the Justices.

Boston ScientificThings got more interesting during the presentation by counsel for Boston Scientific.  As opposed to the Federal Circuit, which focused the inquiry on which party was disturbing the status quo, it appeared as though the starting point for the Justices was that the courts should look to the appropriate mirror-image coercive action, as is done in other declaratory judgment actions.  Therefore, in this case, the court would focus on the infringement suit that the patent holder would bring if the licensee breached the contract.  For example, Chief Justice Roberts referred to this as the "elephant in the room":  "the relief they are seeking is protection against the relief that you would be seeking but for the declaratory judgment action."  However, this is not exactly correct, because with the license in place, the patent holder could not bring an infringement action.  For example, when Justice Kennedy pointed out that "if [the licensee] refused to pay the royalty . . . then there would have been infringement," counsel for Boston Scientific correctly pointed out:  "[b]ut then you're changing all the facts around.  That's not - - that's not what we're dealing with in this case."  The problem is that when you start by looking to what the mirror-image coercive action would be, the burden is pre-determined.  Thus, if the Court follows through with this reasoning, they almost certainly will shift the burden of proof back to the patent holder MedImmune-like cases.

This is the heart of the problem with the MedImmune decision.  Assigning the burden of proof to either party results in a situation that is not necessarily fair to that party, and does not necessarily logically follow.  This problem was highlighted by the questions and comments from Justice Scalia, which is interesting considering he was the author of the MedImmune opinion.  First, Justice Scalia appeared to be so focused on MedImmune-type declaratory judgment actions that this exceptional-type case appeared to overshadow the typical declaratory-judgment actions.  For example, in responding to Boston Scientific's argument that no patent infringement counterclaim could be brought, Justice Scalia stated that it seemed to him "it is often the case in declaratory judgment actions that the defendant in the action cannot counterclaim."  This may be true if you are only considering MedImmune-type cases.  However, the Article III case-or-controversy requirement necessary for all declaratory-judgment actions almost requires that the DJ defendant be able to bring a counterclaim -- otherwise the requirement would not be met.  For example, in patent infringement declaratory-judgment actions (where there is no license), the potential infringer brings suit to gain certainty that it can make, use, or sell its product without fear that a patent will be asserted against it.  In such cases, the patent holder is certainly able to bring an infringement counterclaim.  In fact, without the threat of such an infringement action, the Article III case-or-controversy requirement would be lacking.  Nevertheless, Justice Scalia stated that "[t]he whole purpose of the declaratory judgment statue is to enable you to sue before the other side has a cause of action against you."  However, this does not comport with the requirements of Article III.  In fact, Justice Scalia summarized the standard in the MedImmune case as:  "Basically, the question in each case is whether the facts alleged, under all the circumstances, show that there is a substantial controversy, between parties having adverse legal interests, of sufficient immediacy and reality to warrant the issuance of a declaratory judgment."  MedImmune, 549 U.S. at 127.  It is because these MedImmune-type actions have a somewhat "artificial" satisfaction of the case-or-controversy requirement (because there is no infringement) that causes the problems that arise in these sorts of cases.

Justice Scalia also brought up the "res judicata problem," which also stems from the artificial nature of these MedImmune-type actions.  The hypothetical was explained as such by Justice Scalia:

Let's assume that we put the burden of proof where you want it.  Okay?  So this declaratory judgment action is defeated.  All right?  Nonetheless, they say:  Still and all, we are going to go ahead and not pay any royalties.  And then you bring - - you bring an infringement action, right?

In this hypothetical, the parties would need to relitigate the entire case.  This is because in MedImmune-type declaratory judgment action, as Justice Scalia put it, the best that the patent holder can establish "is that [the licensee] didn't prove non-infringement."  Or, as Boston Scientific's counsel put it, the issue in the declaratory judgment action is claim coverage, but the issue in the subsequent litigation is infringement.  Therefore, there would be no issue preclusion in the subsequent "breach" patent infringement litigation, and therefore the patent holder would need to prove infringement to be entitled to remedies.  This "res judicata problem" is an unfortunate consequence of the MedImmune decision.

Finally, the counsel for Boston Scientific continued to stress that it is important to look at what remedy is being sought to determine who has the burden of proof.  Because the patent holder cannot seek any remedies, he argued, the burden should be with the licensee.  The Court did not seem convinced.  Interestingly, near the end of the hearing, Justice Scalia appeared to have recognized the sought-after remedy in this case:

[T]hey don't want to continue to pay royalties.  That's the point.  That's why they bring the Declaratory Judgment Act [sic], so that the court can tell them:  You don't have to pay royalties because this stuff is not covered.

To this, counsel for Boston Scientific responded:  "that's absolutely right."  If the Court focuses on this remedy, instead of analyzing what the mirror-image coercive action would be, it is possible that it could require the licensee to bear the burden of proof in these cases.  Nevertheless, it did not appear that the Justices were convinced that the burden should be any different in MedImmune-type cases than they are in standard "mirror-image coercive" declaratory-judgment actions.

Of course, it is impossible to be certain what the outcome of any case will be based on the questioning from the bench.  We will, of course, provide an analysis when the Court issues its opinion, which should occur before the end of June, 2014.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.